Clinical trials: VITILIGO
Adipose-derived Stem Cells, Excimer Light
Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.
- Conditions
- Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
- Trial name
- NCT07690501
- Testing
- Adipose-derived Stem Cells Combined With Excimer Light
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Tanta University
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Non Segmental Vitiligo
ICP-332 in Subjects With Non-segmental Vitiligo
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an…
- Trial name
- NCT07047612
- Testing
- ICP-332 Tablets
- Where
- 45 sites in China
- Volunteers
- 603 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Non-Segmental Vitiligo
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color.
- Trial name
- Ph3 Peds Viti (NCT07896434)
- Testing
- Upadacitinib
- Volunteers
- 154 people
- Sponsor
- AbbVie
Vitiligo Vulgaris
Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents
Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. One study investigating the use of Ginkgo biloba for the treatment of vitiligo in adults reports effectiveness…
- Trial name
- NCT00907062
- Testing
- Ginkgo biloba
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Vitiligo
5-fluorouracil for Treatment of Stable Vitiligo
Vitiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. Despite various existing medical approaches, current vitiligo treatments are still far from optimal.
- Trial name
- NCT06209138
- Testing
- 5 fluorouracil, Saline
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance
Measure of Acceptance of chRonic Visible sKin conditionS
The objective of this protocol is to validate 4 scales for evaluating the acceptance of visible chronic dermatological diseases (port wine stains, alopecia areata, vitiligo, hyperpigmentation...) with a large number of patients…
- Conditions
- Acceptance of Visible Chronic Dermatological Disease, Disease Acceptance, Psychological Well-Being, Social Segregation
- Trial name
- MARKS (NCT06103903)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Tours
Vitiligo, Generalized
Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy
The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2.
- Trial name
- NCT06546059
- Testing
- narrow band ultraviolet-B
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- South Valley University
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Vitiligo
Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck
To determine the optimal treatment frequency of 308-nm excimer laser for vitiligo and identify the key clinical variable(s) associated with the treatment efficiency under the optimal treatment frequency.
- Trial name
- NCT00368407
- Testing
- 308-nm excimer laser
- Where
- China
- Sponsor
- Air Force Military Medical University, China
Autophagy
Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo
The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.
- Trial name
- NCT03371758
- Testing
- skin biopsy
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cairo University
Non-segmental Vitiligo
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not…
- Trial name
- NCT04057573
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 76 sites in United States, Bulgaria and 7 more
- Volunteers
- 344 people
- Sponsor
- Incyte Corporation
Non-segmental Vitiligo
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)
- Trial name
- NCT07105254
- Testing
- Roflumilast topical 0.3% foam
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Texas, PLLC
Dermatologic Disease, Vitiligo
Vitiligo Registry for Adults and Children in the UK
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years…
- Trial name
- VIRTUAL-UK (NCT06218082)
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Vitiligo
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
The study will compare the effectiveness of combined treatment with NB-UVB and tacrolimus versus NB-UVB alone . Patients will be treated for 6 months and followed up after 3 months .All types of vitiligo will be included except…
- Trial name
- NCT03199664
- Testing
- NB-UVB, NB-UVB & Tacrolimus 0.03%
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- South Valley University
Metabolic Syndrome, Vitiligo
Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo
This study aims at detection of possible associated metabolic syndrome with vitiligo and assessment of possible contribution of the age of onset of vitiligo.
- Trial name
- NCT03622320
- Testing
- Blood sample
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Cairo University
Vitiligo
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.
- Trial name
- GB (NCT01006421)
- Testing
- GINGKO BILOBA
- Where
- Saudi Arabia
- Volunteers
- 160 people
- Sponsor
- King Saud University
Vitiligo
Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo
Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients with Non-segmental Vitiligo before and after phototherapy
- Trial name
- NCT05121532
- Testing
- Interleukin-15 and Interleukin-22
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University